| Literature DB >> 36239712 |
Kyung Min Lim1, Ji-Hye Han2, Yoonjoo Lee1, Junghee Park2, Ahmed Abdal Dayem1, Seung-Hyun Myung2, Jongyub An1, Kwonwoo Song1, Geun-Ho Kang3, Sejong Kim3, Sangwoo Kwon4, Kyung Sook Kim4, Ssang-Goo Cho1,3, Tae-Hyoung Kim2,5.
Abstract
Extracellular vesicles (EVs) are nano-sized membranous structures involved in intercellular communication and various physiological and pathological processes. Here, we present a novel method for rapid (within 15 min), large-scale production of high-purity EVs using eMTDΔ4, a peptide derived from Noxa. The treatment of mesenchymal stem cells derived from human Wharton's jelly after trypsinization and subsequent eMTDΔ4 stimulation in a chemically defined sucrose buffer with orbital shaking led to a substantial increase (approximately 30-fold) in EV production with markedly high purity (approximately 45-fold). These EVs (TS-eEVs) showed higher regenerative and immunomodulatory potential than natural EVs obtained from the culture media after 48 h. The calcium chelator BAPTA-AM and calpain inhibitor ALLM, but not the natural EV biogenesis inhibitor GW4869, blocked the TS-eEV production induced by eMTDΔ4, indicating that the eMTDΔ4-mediated regulation of intracellular calcium levels and calpain activity are closely associated with the rapid, mass production of TS-eEVs. The present study may lead to considerable advances in EV-based drug development and production of stem cell-derived EVs for cell therapy.Entities:
Keywords: EV production; anti-inflammatory potential; drug delivery; eMTDΔ4; extracellular vesicles; mitochondrial targeting domain
Mesh:
Substances:
Year: 2022 PMID: 36239712 PMCID: PMC9563391 DOI: 10.1002/jev2.12274
Source DB: PubMed Journal: J Extracell Vesicles ISSN: 2001-3078